{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=BeOne+Medicines", "query": { "sponsor": "BeOne Medicines" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 72, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=BeOne+Medicines&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T15:16:41.383Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07492641", "title": "BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HR+/HER2- Breast Cancer" ], "interventions": [ { "name": "BGB-43395", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1056, "start_date": "2026-05-22", "completion_date": "2037-08-07", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-07-23T15:16:41.383Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Coral Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07492641" }, { "nct_id": "NCT04170283", "title": "Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B-cell Malignancies" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 955, "start_date": "2020-01-16", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-07-23T15:16:41.383Z", "location_count": 26, "location_summary": "Gilbert, Arizona • Little Rock, Arkansas • Centennial, Colorado + 23 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04170283" }, { "nct_id": "NCT06427941", "title": "A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Hepatocellular Carcinoma", "Local Advanced Hepatocellular Carcinoma", "Alpha-fetoprotein (AFP)-Producing Gastric Cancer", "Extragonadal Yolk Sac Tumors", "Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer" ], "interventions": [ { "name": "BGB-B2033", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 392, "start_date": "2024-07-23", "completion_date": "2028-05-30", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-07-23T15:16:41.383Z", "location_count": 7, "location_summary": "Goodyear, Arizona • Duarte, California • Zion, Illinois + 4 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Zion", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06427941" }, { "nct_id": "NCT05828589", "title": "A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Relapsed Chronic Lymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Relapsed Follicular Lymphoma", "Relapsed Marginal Zone Lymphoma", "Relapse Diffuse Large B Cell Lymphoma", "Relapsed Small Lymphocytic Lymphoma", "Refractory Follicular Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Small Lymphocytic Lymphoma", "Richter Transformation", "Refractory Diffuse Large B-cell Lymphoma", "Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "BGB-21447", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2023-06-20", "completion_date": "2026-06-08", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-07-23T15:16:41.383Z", "location_count": 7, "location_summary": "Washington D.C., District of Columbia • Iowa City, Iowa • Waukee, Iowa + 4 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Waukee", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Mineola", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05828589" }, { "nct_id": "NCT06943872", "title": "A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2025-06-11", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-07-23T15:16:41.383Z", "location_count": 35, "location_summary": "Laguna Hills, California • Orange, California • Palo Alto, California + 31 more", "locations": [ { "city": "Laguna Hills", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06943872" }, { "nct_id": "NCT04746924", "title": "A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer", "NSCLC" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 669, "start_date": "2021-05-24", "completion_date": "2026-03-18", "has_results": true, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-07-23T15:16:41.383Z", "location_count": 9, "location_summary": "Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Goshen", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04746924" }, { "nct_id": "NCT04002297", "title": "A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mantle Cell Lymphoma; Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "zanubrutinib", "type": "DRUG" }, { "name": "bendamustine", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 510, "start_date": "2019-08-20", "completion_date": "2031-09-30", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-07-23T15:16:41.383Z", "location_count": 12, "location_summary": "Orange, California • Chicago, Illinois • Boston, Massachusetts + 9 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT04002297" }, { "nct_id": "NCT04466891", "title": "A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-amplified Biliary Tract Cancers" ], "interventions": [ { "name": "ZW25 (Zanidatamab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2020-10-01", "completion_date": "2024-07-11", "has_results": true, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-07-23T15:16:41.383Z", "location_count": 14, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Duarte, California + 11 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04466891" }, { "nct_id": "NCT03336333", "title": "A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2017-10-31", "completion_date": "2027-10-31", "has_results": true, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-07-23T15:16:41.383Z", "location_count": 18, "location_summary": "Augusta, Georgia • Chicago, Illinois • Boston, Massachusetts + 13 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03336333" }, { "nct_id": "NCT06756932", "title": "BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hormone-receptor-positive Breast Cancer", "HER2-negative Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "BGB-21447", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "BGB-43395", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-02-04", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-07-23T15:16:41.383Z", "location_count": 3, "location_summary": "Iowa City, Iowa • Houston, Texas • Seattle, Washington", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06756932" } ] }